

The following is a list of publications written by GSID researchers and our colleagues.

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL Jr, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, Harrison SC, Haynes BF. Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion. J. Virol. JVI.00718-12; published ahead of print 21 November 2012. doi: 10.1128/JVI.00718-12 JVI.00718-12	2012	HIV
Nicos Karasavvas, Erik Billings, Mangala Rao, Constance Williams, Susan Zolla-Pazner, Robert T. Bailer, Richard A. Koup, Sirinan Madnote, Duangnapa Arworn, Xiaoying Shen, Georgia D. Tomaras, Jeffrey R. Currier, Mike Jiang, Craig Magaret, Charla Andrews, Raphael Gottardo, Peter Gilbert, Timothy J. Cardozo, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Punnee Pitisuttithum, Jaranit Kaewkungwal, Robert Paris, Kelli Greene, Hongmei Gao, Sanjay Gurunathan, Jim Tartaglia, Faruk Sinangil, Bette T. Korber, David C. Montefiori, John R. Mascola, Merlin L. Robb, Barton F. Haynes, Viseth Ngauy, Nelson L. Michael, Jerome H. Kim, and Mark S. de Souza, for the MOPH TAVEG Collaboration. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses. November 2012, 28(11): 1444-1457. doi: 10.1089/aid.2012.0103	2012	HIV
O'Rourke SM, Schweighardt B, Phung P, Mesa KA, Vollrath AL, Tatsuno GP, To B, Sinangil F, Limoli K, Wrin T, Berman PW. Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29.	2012	HIV
Donald P. Francis. Deadly AIDS policy failure by the highest levels of the US government: a personal look back 30 years later for lessons to respond better to future epidemics. Journal of Public Health Policy (2012) 33, 290–300. doi:10.1057/jphp.2012.14	2012	HIV

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Prem Sri N, Namwat C, Bowonwatanuwong C, Li SS, Kaewkungkal J, Trichavaroj R, Churikanont N, de Souza MS, Andrews C, Francis D, Adams E, Flores J, Gurunathan S, Tartaglia J, O'Connell RJ, Eamsila C, Nitayaphan S, Ngauy V, Thongcharoen P, Kunasol P, Michael NL, Robb ML, Gilbert PB, Kim JH. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis. first published online July 26, 2012 doi:10.1093/infdis/jis478.	2012	HIV
R.T. Mahoney, D.P. Francis , N.M. Frazatti-Gallina, A.R. Precioso, I. Raw, P. Watler, P. Whitehead, S.S. Whitehead, Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil, Vaccine, Volume 30, Issue 32, 6 July 2012, Pages 4892-4896, ISSN 0264-410X, 10.1016/j.vaccine.2012.02.064.	2012	Dengue
Donald P. Francis . Protecting the public's health: remove the political constraints that hamper the Centers for Disease Control and Prevention, AIDS. 2012 Jun 1;26(9):1175-6. doi:10.1097/QAD.0b013e32835392dd	2012	CDC
David C. Montefiori, Chitraporn Karnasuta, Ying Huang, Hasan Ahmed, Peter Gilbert, Mark S. de Souza, Robert McLinden, Sodsai Tovanabutra, Agnes Laurence-Chenine, Eric Sanders-Buell, M. Anthony Moody, Mattia Bonsignori, Christina Ochsenbauer, John Kappes, Haili Tang, Kelli Greene, Hongmei Gao, Celia C. LaBranche, Charla Andrews, Victoria R. Polonis, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Steve G. Self, Phillip W. Berman, Donald Francis , Faruk Sinangil , Carter Lee , Jim Tartaglia, Merlin L. Robb, Barton F. Haynes, Nelson L. Michael, and Jerome H. Kim. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials J Infect Dis. (2012) 206(3): 431-441. doi:10.1093/infdis/jis367	2012	HIV

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Merlin L Robb MD, Supachai Rerks-Ngarm MD, Sorachai Nitayaphan MD, Prof Punnee Pitisuttithum MD, Jaranit Kaewkungwal PhD, Prayura Kunasol MD, Chirasak Khamboonruang MD, Prof Prasert Thongcharoen MD, Patricia Morgan MS, Michael Benenson MD, Robert M Paris MD, Joseph Chiu MD, Elizabeth Adams MD, Donald Francis MD , Sanjay Gurunathan MD, Jim Tartaglia PhD, Peter Gilbert PhD, Don Stablein PhD, Nelson L Michael MD, Dr Jerome H Kim MD. Risk behavior and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 531 - 537, July 2012. DOI: 10.1016/S1473-3099(12)70088-9	2012	HIV
Kathryn E. Stephenson, John Hural, Susan P. Buchbinder, Faruk Sinangil , and Dan H. Barouch. Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials J Infect Dis. (2012) 205(12): 1806-1810 first published online April 5, 2012 doi:10.1093/infdis/jis285	2012	HIV
Arita, Isao and Donald P. Francis . Safe landing for global polio eradication: A Perspective. Vaccine. 29 (2011) 8827-34	2011	Polio
Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F , de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18;29 (32):5203-9. Epub 2011 May 25. doi:10.1016/j.vaccine.2011.05.025	2011	HIV

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F , Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. J Virol. 2011 Oct;85(19):9998-10009. Epub 2011 Jul 27. doi:10.1128/JVI.05045-11	2011	HIV
Francis, Donald P. and Gary Grohmann. WHO Influenza vaccine technology transfer initiative: Role and activities of the Technical Advisory Group. Vaccine 295 (2011) A45-A47. doi:10.1016/j.vaccine.2011.02.078	2011	Influenza
Mahoney R, Chocarro L, Southern J, Francis DP , Vose J, Margolis H. Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries. PLoS Med 8(2): e1000418. Published February 22, 2011. doi:10.1371/journal.pmed.1000418.	2011	Dengue
Pérez-Losada M, Jobes DV, Sinangil F , Crandall KA, Arenas M, Posada D, Berman PW. Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. PLoS One. 2011 Mar 10;6(3):e16902. doi:10.1371/journal.pone.0016902	2011	HIV
Pitisuttihum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, Suntharasamai P, Vanijanonta S, Nitayapan S, Kaewkungwal J, Benenson M, Morgan P, O'Connell R, Berenberg J, Gurunathan S, Francis DP , Paris R, Chiu J, Stablein D, Michael NL, Excler JL, Rob M, Kim J. Jerome H. Kim. Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS Vol 6, Issue 12, e27837, December 2011.	2011	HIV
The Ministry of Public Health – Thai AIDS Vaccine Evaluation Group (MOPH-TAVEG). Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29 (2011) 4285-4292. doi:10.1016/j.vaccine.2011.03.014	2011	HIV
Francis DP. Successes and failures: Worldwide vaccine development and application. Biologicals. 2010 Sep;38(5):523-8. Epub 2010 Aug 4. Review. doi:10.1016/j.biologicals.2010.06.003	2010	General

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Francis, Don , Douglas D, Mahoney R. The manufacture and supply of dengue vaccine. Occasional Paper, Pediatric Dengue Vaccine Initiative, International Vaccine Institute, December 2010.	2010	Dengue
Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F , D'Souza P, Rodriguez-Chavez IR, Decamp A, Giganti M, Berman PW, Self SG, and Montefiori DC. Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. <i>J Infect Dis</i> 202 (4): 595-605 (2010). doi: 10.1086/654816	2010	HIV
O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, Sinangil F , Berman PW. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. <i>J Virol.</i> 2010 Nov;84(21):11200-9. doi:10.1128/JVI.00790-10	2010	HIV
Perez-Losada M, Jobes DV, Sinangil F , , and Crandall KA, Posada D, and Berman PW. Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America. <i>Mol Biol Evol</i> 27(2):417-25 (2010). doi: 10.1093/molbev/msp254	2010	HIV
Smith DH, Winters-Digiaccio P, Mitiku M, O'Rourke S, Sinangil F , Wrin T, Montefiori DC, Berman PW. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. <i>PLoS One</i> 5(8): e12076. Doi:1371/journal.pone.0012076 (2010)	2010	HIV
O'Rourke SM, Schweighardt B, Scott W, Wrin T, Fonseca D, Sinangil F , and Berman PW. Novel ring structure in the gp41 trimer of human deficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. <i>J Virol.</i> 83(15):7728-38 (2009). doi:10.1128/JVI.00688-09	2009	HIV
Perez-Losada M, Posada D, Jobes DV, Sinangil F , Berman PW, and Crandall KA. Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. <i>Retrovirology</i> 6:67 (2009). doi:10.1186/1742-4690-6-67	2009	HIV
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premisri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP , Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. <i>N Engl J Med.</i> 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20. doi:10.1056/NEJMoa0908492	2009	HIV

<u>Publications by GSID</u>	<u>Year</u>	<u>Field</u>
Pitisuttithum P, Choopanya K, Bussaratid V, Vanichseni S, van Griensven F, Phonrat B, Martin M, Vimutsunthorn E, Sangkum U, Kitayaporn D, Tappero JW, Heyward W, Francis D . Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai. 2007 Nov;90(11):2442-8.	2007	HIV
Jobs DV, Daoust M, Nguyen V, Padua A, Michele S, Lock MD, Chen A, Sinangil F , and Berman PW. High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV-1 infections from a Phase 3 vaccine efficacy trial. AIDS Res Hum Retroviruses 22 (10):1014-21 (2006). doi:10.1089/aid.2006.22.1014	2006	HIV
Jobs DV, Daoust M, Nguyen V, Padua A, Sinangil F , Perez-Losada M, Crandall KA, Oliphant T, Posada D, Rambaut A, Fuchs J, Berman PW. Longitudinal population analysis of dual infection with recombination in two strains of HIV-1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. AIDS Res Hum Retroviruses 22 (10): 968-78 (2006). doi: 10.1089/aid.2006.22.968	2006	HIV